Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Nicolina Conti, Milo Gatti, Emanuel Raschi, Igor Diemberger & Luciano Potena. (2021) Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. Drug Design, Development and Therapy 15, pages 3391-3409.
Read now
Read now
Hulya Akhan Kasikcioglu & Nese Cam. (2006) A review of levosimendan in the treatment of heart failure. Vascular Health and Risk Management 2:4, pages 389-400.
Read now
Read now
Leif Erhardt. (2005) An emerging role for calcium sensitisation in the treatment of heart failure. Expert Opinion on Investigational Drugs 14:6, pages 659-670.
Read now
Read now
Stefan D Anker, Ewa A Jankowska & Darlington O Okonko. (2004) Therapeutic patents for chronic heart failure: a review of patent applications from 1996 to 2002. Expert Opinion on Therapeutic Patents 14:5, pages 639-654.
Read now
Read now
Articles from other publishers (19)
Daniele Masarone, Michelle M. Kittleson, Piero Pollesello, Marco Marini, Massimo Iacoviello, Fabrizio Oliva, Angelo Caiazzo, Andrea Petraio & Giuseppe Pacileo. (2022) Use of Levosimendan in Patients with Advanced Heart Failure: An Update. Journal of Clinical Medicine 11:21, pages 6408.
Crossref
Crossref
Daniel Burkhoff, Stuart Rich, Piero Pollesello & Zoltán Papp. (2021) Levosimendan‐induced venodilation is mediated by opening of potassium channels. ESC Heart Failure 8:6, pages 4454-4464.
Crossref
Crossref
Younss Ait Mou, Christian Bollensdorff, Olivier Cazorla, Yacoub Magdi & Pieter P. de Tombe. (2015) Exploring cardiac biophysical properties. Global Cardiology Science and Practice 2015:1, pages 10.
Crossref
Crossref
Y Kalam & A Graudins. (2012) Levosimendan infusion improves cardiac output but not blood pressure in a rodent model of severe metoprolol toxicity. Human & Experimental Toxicology 31:9, pages 955-963.
Crossref
Crossref
Yasmean Kalam & Andis Graudins. (2012) Levosimendan Does Not Improve Cardiac Output or Blood Pressure in a Rodent Model of Propranolol Toxicity When Administered Using Various Dosing Regimens. International Journal of Toxicology 31:2, pages 166-174.
Crossref
Crossref
E F Du Toit, A Genis, L H Opie, P Pollesello & A Lochner. (2008)
A role for the RISK pathway and K
ATP
channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart
. British Journal of Pharmacology 154:1, pages 41-50.
Crossref
Crossref
John G. F. Cleland. 2008. Acute Heart Failure. Acute Heart Failure
885
891
.
Piero Pollesello & Zoltán Papp. (2007) The Cardioprotective Effects of Levosimendan: Preclinical and Clinical Evidence. Journal of Cardiovascular Pharmacology 50:3, pages 257-263.
Crossref
Crossref
Jun Zhang, Eric M. Gage, Qin C. Ji & Tawakol A. El-Shourbagy. (2007) A strategy for high-throughput analysis of levosimendan and its metabolites in human plasma samples using sequential negative and positive ionization liquid chromatography/tandem mass spectrometric detection. Rapid Communications in Mass Spectrometry 21:14, pages 2169-2176.
Crossref
Crossref
Damien Barraud, Valérie Faivre, Thibault Damy, Stéphane Welschbillig, Etienne Gayat, Christophe Heymes, Didier Payen, Ajay M. Shah & Alexandre Mebazaa. (2007) Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: Comparison with dobutamine and milrinone. Critical Care Medicine 35:5, pages 1376-1382.
Crossref
Crossref
Athanasios Trikas, Charalambos Antoniades, Giorgos Latsios, Karmen Vasiliadou, Ioannis Karamitros, Dimitris Tousoulis, Costantinos Tentolouris & Christodoulos Stefanadis. (2006) Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. European Journal of Heart Failure 8:8, pages 804-809.
Crossref
Crossref
David A. KassR. John Solaro. (2006) Mechanisms and Use of Calcium-Sensitizing Agents in the Failing Heart. Circulation 113:2, pages 305-315.
Crossref
Crossref
John G.F. Cleland, Nick Freemantle, Alison P. Coletta & Andrew L. Clark. (2006) Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. European Journal of Heart Failure 8:1, pages 105-110.
Crossref
Crossref
John Dernellis & Maria Panaretou. (2005) Effects of Levosimendan on Restrictive Left Ventricular Filling in Severe Heart Failure. Chest 128:4, pages 2633-2639.
Crossref
Crossref
Reiko Takahashi & Masao Endoh. (2005)
Dual regulation of myofilament Ca
2
+
sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium
. British Journal of Pharmacology 145:8, pages 1143-1152.
Crossref
Crossref
Douglas L. MannMichael R. Bristow. (2005) Mechanisms and Models in Heart Failure. Circulation 111:21, pages 2837-2849.
Crossref
Crossref
Piero Pollesello & Alexandre Mebazaa. (2004) ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Current Opinion in Critical Care 10:4, pages 436-441.
Crossref
Crossref
Masao Endoh. (2004)
A Na
+
channel agonist: a potential cardiotonic agent with a novel mechanism?
. British Journal of Pharmacology 143:6, pages 663-665.
Crossref
Crossref
Stephan von Haehling, Gerhard-Paul Diller & Stefan D. Anker. (2004) Impact of levosimendan treatment on chronic heart failure. The American Journal of Cardiology 94:8, pages 1105.
Crossref
Crossref